What're The Applications of 3D Printing in Drug Delivery

 
WATERTOWN, Mass. - Jan. 21, 2022 - PRLog -- 3D printing (3DP) technology has been repurposed to apply to pharmaceutical development, in recent years it has been used to produce tablets of personalized dosage and combine several prescriptions into one tablet. Future possible developments discuss methods of sustained release and the ability to integrate into sites of injury or trauma specifically to assist the healing process.

The First 3DP Drug on the Market

The first 3DP drug was approved for usage in 2015. Used for treating epilepsy, specifically partial-onset seizures in children of 4 years, myoclonic seizures in ages 12 and over with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in ages 6 and older.

The manufacturer of the drug copyrighted its technology to develop the porous and rapidly disintegrating structure. This technology simplifies ink formation and allows the production of high-dose medicines. This method allows for rapid scaled-up production, but it is difficult to use to personalize medicine and combine drugs due to the different powdered ingredients needed to be layered precisely between print passes. The benefits of such a tablet are the ease of administration by self or carer, the high dosage ability of one tablet, and the rapid mode of action.

Combining Medication into an Easy-To-Swallow Pill

The act of combining several drugs into one pill is not a novel idea, but one that is facilitated by the use of 3DP. The commercially available polypill called "Polycap" is a five-in-one dosage for the prevention of cardiovascular events and stroke.

A 2015 study managed to combine the same 5 drugs and observed their sustained release profiles by using 3DP. These drugs were physically separated using cellulose-based materials. Though, there are issues with which drugs can be combined into polypills, such as those that are susceptible to heat-induced degradation as they cannot withstand the >200°C heat-based deposition of a 3D printer. There were few reports of a pill with a single drug formulation with multiple release mechanisms at the time of this study. Other notable issues involved ink bleeding and migration as a result of printing larger doses.

Conclusion

From its advent, 3DP was a game-changing technology that revolutionized several different industries. Its impact on drug production and delivery has eased the development of easy to administer and easy to swallow pills. Though there is only one 3DP drug on the market, there is every possibility for more to be developed in the near future.

Biopharma PEG caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale. And we can provide PEG derivatives AC-PEG-AC (https://www.biochempeg.com/product/AC-PEG-AC.html) and AC-PEG-RGD (https://www.biochempeg.com/product/AC-PEG-RGD.html) for 3D bioprinting.

Contact
Sonia Li
***@biochempeg.com
End
Source: » Follow
Email:***@biochempeg.com
Posted By:***@biochempeg.com Email Verified
Tags:3D bioprinting
Industry:Business
Location:Watertown - Massachusetts - United States
Subject:Products
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Biopharma PEG Scientific Inc. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share